Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.46 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27732531 | 1.00 | SRC (0.53) | SRCTAAR1HTR2AALDH1A1GABBR2 | |
| SCHEMBL28043476 | 0.98 | SRC (0.52) | SRCTAAR1HTR2AALDH1A1GABBR2 | |
| SCHEMBL3398560 | 0.83 | SRC (0.53) | SRCALDH1A1CYP2D6CYP2C19LMNA | |
| SCHEMBL249115 | 0.83 | SRC (0.53) | SRCALDH1A1CYP2D6CYP2C19LMNA | |
| SCHEMBL3398553 | 0.83 | SRC (0.53) | SRCALDH1A1CYP2D6CYP2C19LMNA | |
| SCHEMBL14955046 | 0.83 | SRC (0.57) | SRCALDH1A1CYP2D6CYP2C19LMNA | |
| SCHEMBL14955287 | 0.83 | SRC (0.57) | SRCALDH1A1CYP2D6CYP2C19LMNA | |
| SCHEMBL5159231 | 0.81 | SRC (0.55) | SRCALDH1A1CYP2D6CYP2C19LMNA | |
| SCHEMBL3376828 | 0.81 | TAAR1 (0.50) | TAAR1HTR2AGABBR2GABBR1SLC6A2 | |
| SCHEMBL27792875 | 0.80 | GABBR2 (0.59) | GABBR2GABBR1SLC6A4SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103601654-B | A kind of preparation method of taurine substitute | HUANGGANG FUCHI PHARMACEUTICAL CO., LTD. (CN) | 2015-12-09 | — | — | CN | claimed |
| CN-106279023-B | 3,4, 5-trisubstituted pyrazole compound, preparation method, pharmaceutical composition and application | 中国科学院上海药物研究所 | 2021-06-22 | — | — | CN | disclosed |
| CN-103601654-B | A kind of preparation method of taurine substitute | HUANGGANG FUCHI PHARMACEUTICAL CO., LTD. (CN) | 2015-12-09 | — | — | CN | disclosed |
| EP-2932971-A1 | KETAMINE FORMULATIONS | Otonomy, Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| US-8771746-B2 | Colloidal suspensions comprising a therapeutic agent and squalene | OTONOMY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| CN-101851181-B | Preparation method of 1-substituted taurine | UNIV BEIJING CHEMICAL | 2013-09-18 | — | — | CN | disclosed |
| CN-101851182-B | Salt-free preparation method for substituted taurine | UNIV BEIJING CHEMICAL | 2013-07-17 | — | — | CN | disclosed |
| US-20120208848-A1 | GACYCLIDINE FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208851-A1 | FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| CN-101337914-B | Preparation method of taurine and substituted taurine | UNIV BEIJING CHEMICAL | 2012-04-04 | — | — | CN | disclosed |
| WO-2010066450-A1 | A METHOD FOR PREPARING SULFUR-CONTAINING COMPOUNDS | THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2009155421-A1 | GACYCLIDINE FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155401-A1 | FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| CN-101337914-A | Method for preparing taurine and substituted taurine | UNIV BEIJING CHEMICAL (CN) | 2009-01-07 | — | — | CN | disclosed |
| CN-101255126-A | Preparation of taurine and derivatives thereof | UNIV BEIJING (CN) | 2008-09-03 | — | — | CN | disclosed |
| CN-101163481-A | Improved gacyclidine formulations | NEUROSYSTEC CORP (US) | 2008-04-16 | — | — | CN | disclosed |
| EP-1861104-A2 | IMPROVED GACYCLIDINE FORMULATIONS | Neurosystec Corporation (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20060205789-A1 | Gacyclidine formulations | NEUROSYSTEC CORPORATION (US) | 2006-09-14 | — | — | US | disclosed |
| WO-2006096518-A2 | IMPROVED GACYCLIDINE FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2006-09-14 | — | — | WO | disclosed |
| US-4785098-A | BLUE DYES FOR CELLULOSE | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208848-A1 | GACYCLIDINE FORMULATIONS | DCTD, TYMP, TYMS | SRC 4677/4885TAAR1 3085/4885HTR2A 1134/4885 |
| US-20060205789-A1 | Gacyclidine formulations | DCTD, TYMP, TYMS | SRC 4677/4885TAAR1 3085/4885HTR2A 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.